Medicare AdvantageCoverageLow impact
MA08.133d, Evinacumab-dgnb (Evkeeza®)
Independence Blue Cross·Cardiology, Endocrinology, Internal Medicine·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.133d for Evinacumab-dgnb (Evkeeza®) has been updated effective October 1, 2025. This is a pharmacy policy change affecting coverage or authorization requirements for this cholesterol-lowering medication used for homozygous familial hypercholesterolemia.
Action Required
Review updated policy MA08.133d for Evinacumab-dgnb (Evkeeza®) coverage requirements. Billing team should verify current prior authorization requirements and coverage criteria for this specialty cholesterol medication when submitting claims to Medicare Advantage plans.